相关实验视频

Updated: Jun 8, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

在心力衰竭患者中,左束支部区域节奏与内心再同步对比

Juan Carlos Diaz^1,2, Oriana Bastidas^1,2, Julian Aristizabal^2,3

¹Division of Cardiology, Cardiac Arrhythmia and Electrophysiology Service, Clinica Las Vegas, Medellin, Colombia.

Journal of cardiovascular electrophysiology

|November 8, 2024

概括

左捆支部区域节奏 (LBBAP) 和内心心脏心脏再同步治疗 (Endo-CRT) 显示了类似的心力衰竭结果. 与Endo-CRT相比,LBBAP与更短的手术时间和降低中风风险有关.

科学领域:

心脏病学心脏病学
电力生理学电力生理学
心脏衰竭管理的管理

背景情况:

左束枝区域节奏 (LBBAP) 和内心心脏心脏再同步疗法 (Endo-CRT) 是传统的双心室节奏替代CRT的新兴选择.
这些技术旨在通过优化心室脱极化来改善心力衰竭的结果.

研究的目的:

在需要CRT的心力衰竭 (HF) 患者中,比较LBBAP与Endo-CRT的临床结果.
这项研究在LBBAP和Endo-CRT手术中采用了传统的节奏指导.

主要方法:

一项比较研究包括223名接受LBBAP (n=197) 或Endo-CRT (n=26) 的CRT患者.
主要疗效终点:与HF相关的住院和所有原因死亡率的组合. 主要安全终点:与程序相关的并发症.
二级终点包括程序特征,心电图和心声图参数.

主要成果:

在LBBAP和Endo-CRT组之间的初级疗效结果 (死亡率和HF住院) 中没有发现显著差异.
与Endo-CRT组相比,接受LBBAP的患者的光镜时间明显缩短.
在随访期间,LBBAP组的中风发病率较低 (0%对11.5%,p=0.001).

结论:

使用常规引线的LBBAP和Endo-CRT都产生了可比的死亡率,HF住院和左心室喷射率 (LVEF) 改善.
内体CRT与更长的光镜时间和更高的中风风险有关.
LBBAP提供了一个潜在的更安全的替代方案,并提高了程序效率.

关键词:

心脏再同步治疗心脏再同步治疗内心心脏再同步的同步.心脏衰竭是因为心脏衰竭.左捆分支机构地区节奏节奏.

更多相关视频

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...